Refine
Document Type
- Article (61) (remove)
Language
- English (61)
Has Fulltext
- yes (61)
Is part of the Bibliography
- no (61)
Keywords
- SARS-CoV-2 (29)
- COVID-19 (19)
- Omicron (5)
- PCR (5)
- coronavirus (4)
- antiviral therapy (3)
- vaccination (3)
- Autopsy (2)
- BA.1 (2)
- COVID-19 surveillance (2)
- PRNT (2)
- SARS-CoV-2 monitoring (2)
- SARS‐CoV‐2 (2)
- corona virus (2)
- disease burden (2)
- hepatitis B (2)
- in vitro (2)
- infectivity (2)
- influenza (2)
- neutralizing antibodies (2)
- out-patient paediatrics (2)
- respiratory tract infection (2)
- saliva (2)
- sub-lineage (2)
- vaccine (2)
- 17‐OH itraconazole (1)
- 2-deoxy-d-glucose (1)
- 2019-nCoV (1)
- ACE inhibitor (1)
- ALF (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- Ag-RDT (1)
- Anti-CMV IgG (1)
- Antigen test (1)
- B.1.1.529 (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BA.4 (1)
- BA.5 (1)
- BNT162b2 (1)
- BNT2b2 (1)
- Bio safety (1)
- Biomarkers (1)
- CD47 (1)
- CMVepidemiology (1)
- COVID 19 (1)
- CPE (1)
- Caco‐2 cells (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell culture (1)
- Cell-to-Cell Spread (1)
- ChAdOx1-S (1)
- Congenital CMVinfection (1)
- Corona virus (1)
- Covid-19 (1)
- Cytomegalovirus (CMV) (1)
- Darunavir (1)
- Detection workflow (1)
- Donor screening (1)
- E protein structure (1)
- EGFR pathway (1)
- ELISA (1)
- ER stress (1)
- Endothelial cells (1)
- Epsilon (1)
- FFP3 respirator (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Forensic medicine (1)
- HBV (1)
- HCC recurrence (1)
- HCV (1)
- HEV (1)
- HSCT (1)
- Health care workers (1)
- Hepatitis c (1)
- Heterologous prime-boost (1)
- Human immunodeficiency virus (HIV) (1)
- Hypertension (1)
- IAP (1)
- IFA (1)
- IRF-3 (1)
- IgG (1)
- Immunogenicity (1)
- In vitro (1)
- Inactivation (1)
- Inflammation (1)
- Interferon (1)
- Kappa (1)
- Medical history (1)
- Multivariate analysis (1)
- N501Y (1)
- NF-kB (1)
- NGS (1)
- Omicron variant BA.1 (1)
- Otorhinolaryngological (1)
- PAPR (1)
- POCT (1)
- Pandemic (1)
- Pathology (1)
- Personal protective equipment (1)
- Post mortem examination (1)
- Powered air-purifying respirator (1)
- Protein-translocation (1)
- Proteomics (1)
- Quarantine (1)
- RT-PCR-detection (1)
- Reactogenicity (1)
- SARS CoV 2 (1)
- SARS coronavirus (1)
- SARS-CoV-2 testing (1)
- SARS-CoV-2-specific T cells (1)
- SIRPalpha (1)
- SR-BI (1)
- SVR (1)
- Serology (1)
- Seroprevalence (1)
- Stability (1)
- Travel regulations (1)
- Variant of concern (1)
- VeroE6‐eGFP cells (1)
- Viral hepatitis (1)
- Virological testing (1)
- Virus trapping (1)
- Wastewater-based epidemiology (WBE) (1)
- acute liver failure (1)
- animal experiments (1)
- animal models (1)
- antibody tests (1)
- antiviral (1)
- antiviral agents (1)
- antiviral drugs (1)
- antiviral signaling (1)
- aprotinin (1)
- benfooxythiamine (1)
- cathepsin L inhibitor (1)
- cell barrier integrity (1)
- cell culture (1)
- cerebrospinal fluid (1)
- chelator (1)
- coagulation (1)
- coagulopathy (1)
- contact lens solution (1)
- delta (1)
- diagnostic test (1)
- direct-acting antivirals (1)
- drug discovery (1)
- drug repurposing (1)
- drug screening (1)
- elderly (1)
- famotidine (1)
- flavivirus entry factor (1)
- gargle lavage (1)
- genetic diversity (1)
- global diversity (1)
- hepatitis B surface antigen (1)
- hepatitis C virus (1)
- hepatitis D (1)
- hepatitis E (1)
- high throughput (1)
- histamine (1)
- host immune response (1)
- human monoclonal antibody (1)
- human-liver chimeric mouse model (1)
- immunity (1)
- immunosenescence (1)
- immunosuppression (1)
- infection model (1)
- inflammation (1)
- interferon induction (1)
- interferon sensitivity (1)
- intranasal administration (1)
- itraconazole (1)
- live cell imaging (1)
- liver transplantation (1)
- mRNA1273 (1)
- mesenchymal stromal cells (1)
- mice (1)
- molecular surveillance (1)
- monkeypox (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- multimorbidity (1)
- nasal swab (1)
- natural selection (1)
- neutralization (1)
- neutralizing antibody (1)
- nucleotide analogue (1)
- orthopoxvirus (1)
- oxLDL (1)
- oxythiamine (1)
- pentose phosphate pathway (1)
- phenotypic screening; (1)
- poxvirus (1)
- prevention (1)
- qRT-PCR detection (1)
- re-emerging virus (1)
- reactivation (1)
- self-collected samples (1)
- semen (1)
- serology (1)
- severe acute respiratory syndrome coronavirus (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- spike mutation (1)
- spike protein (1)
- stem cells (1)
- surrogate ELISA (1)
- tear (1)
- test protocol (1)
- thrombosis (1)
- toll-like receptor (1)
- topical administration (1)
- transduction (1)
- transferrin (1)
- transmission and vector control (1)
- vaccine, (1)
- variant of concern (1)
- variants of concern (1)
- virus (1)
- wastewater-based epidemiology (WBE) (1)
- yellow fever virus (1)
- yellow fever virus tropism (1)
Institute
Hepatitis B virus (HBV) reactivation in immunosuppressed patients can cause considerable morbidity and mortality. The aim of our study was to evaluate factors associated with acute liver failure (ALF) in HBV reactivation. Clinical, laboratory, and virological data of 87 patients with HBV reactivation were analyzed retrospectively. Teno torque virus (TTV) plasma loads were measured as a measure of immune competence. HBV genomes isolated from 47 patients were analyzed by next-generation sequencing. A functional analysis of identified HBsAg mutants was performed. In patients with ALF the diagnosis was significantly later confirmed than in the non-ALF group. Patients diagnosed during immunosuppression had a milder clinical course compared to later diagnosed patients (p = 0.018, OR = 4.17). TTV viral loads did not differ significantly between the two groups. The HBV genomes isolated from ALF patients had higher viral complexity. A mutation in C-region of HBsAg (L216*), was associated with reduced HBsAg production and secretion. Patients diagnosed with HBV reactivation during immunosuppression had a milder clinical course compared to patients diagnosed during immune reconstitution. ALF was associated with higher viral complexity. An HBsAg mutation (L216*) was found to be more frequent in ALF patients and was associated with reduced HBsAg production and secretion.
Introduction: Reliable and cost-effective diagnostics for hepatitis E virus (HEV) infection are necessary. The aim of our study was to investigate which diagnostic test is most accurate to detect HEV infection in immunocompetent and immunosuppressed patients in a real world setting. Patients and Methods: We performed a retrospective analysis of 1165 patients tested for HEV antibodies and HEV PCR at the same time point. Clinical, laboratory and virological data were taken from patient charts. HEV IgA was measured in a subgroup of 185 patients. Results: HEV RNA was detectable in 61 patients (5.2%); most of them (n = 49, 80.3%/n = 43, 70.5%) were HEV IgM+ and IgG+; however, 12 patients (19.6%) were HEV RNA positive/HEV IgM negative and 17 patients (27.8%) were HEV RNA positive/HEV IgG negative. Ten HEV RNA positive patients (16.4%) had neither HEV IgG nor IgM antibodies. Importantly, all of them were immunosuppressed. HEV IgA testing was less sensitive than HEV IgM for HEV diagnosis. Conclusions: HEV infection can be overlooked in patients without HEV specific antibodies. Performing PCR is necessary to diagnose or exclude HEV infection in immunocompromised hosts. In immunocompetent patients, a screening based on HEV antibodies (IgG/IgM) is sufficient.
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S) protein by cellular proteases. Herein, we showed that the protease inhibitor aprotinin (but not the protease inhibitor SERPINA1/alpha-1 antitrypsin) inhibited SARS-CoV-2 replication in therapeutically achievable concentrations. An analysis of proteomics and translatome data indicated that SARS-CoV-2 replication is associated with a downregulation of host cell protease inhibitors. Hence, aprotinin may compensate for downregulated host cell proteases during later virus replication cycles. Aprotinin displayed anti-SARS-CoV-2 activity in different cell types (Caco2, Calu-3, and primary bronchial epithelial cell air–liquid interface cultures) and against four virus isolates. In conclusion, therapeutic aprotinin concentrations exert anti-SARS-CoV-2 activity. An approved aprotinin aerosol may have potential for the early local control of SARS-CoV-2 replication and the prevention of COVID-19 progression to a severe, systemic disease.
SARS-CoV-2 is causing the coronavirus disease 2019 (COVID-19) pandemic, for which effective pharmacological therapies are needed. SARS-CoV-2 induces a shift of the host cell metabolism towards glycolysis, and the glycolysis inhibitor 2-deoxy-d-glucose (2DG), which interferes with SARS-CoV-2 infection, is under development for the treatment of COVID-19 patients. The glycolytic pathway generates intermediates that supply the non-oxidative branch of the pentose phosphate pathway (PPP). In this study, the analysis of proteomics data indicated increased transketolase (TKT) levels in SARS-CoV-2-infected cells, suggesting that a role is played by the non-oxidative PPP. In agreement, the TKT inhibitor benfooxythiamine (BOT) inhibited SARS-CoV-2 replication and increased the anti-SARS-CoV-2 activity of 2DG. In conclusion, SARS-CoV-2 infection is associated with changes in the regulation of the PPP. The TKT inhibitor BOT inhibited SARS-CoV-2 replication and increased the activity of the glycolysis inhibitor 2DG. Notably, metabolic drugs like BOT and 2DG may also interfere with COVID-19-associated immunopathology by modifying the metabolism of immune cells in addition to inhibiting SARS-CoV-2 replication. Hence, they may improve COVID-19 therapy outcomes by exerting antiviral and immunomodulatory effects.
Reliable, easy-to-handle phenotypic screening platforms are needed for the identification of anti-SARS-CoV-2 compounds. Here, we present caspase 3/7 activity as a readout for monitoring the replication of SARS-CoV-2 isolates from different variants, including a remdesivir-resistant strain, and of other coronaviruses in numerous cell culture models, independently of cytopathogenic effect formation. Compared to other models, the Caco-2 subline Caco-2-F03 displayed superior performance. It possesses a stable SARS-CoV-2 susceptibility phenotype and does not produce false-positive hits due to drug-induced phospholipidosis. A proof-of-concept screen of 1,796 kinase inhibitors identified known and novel antiviral drug candidates including inhibitors of phosphoglycerate dehydrogenase (PHGDH), CDC like kinase 1 (CLK-1), and colony stimulating factor 1 receptor (CSF1R). The activity of the PHGDH inhibitor NCT-503 was further increased in combination with the hexokinase II (HK2) inhibitor 2-deoxy-D-glucose, which is in clinical development for COVID-19. In conclusion, caspase 3/7 activity detection in SARS-CoV-2-infected Caco-2-F03 cells provides a simple phenotypic high-throughput screening platform for SARS-CoV-2 drug candidates that reduces false-positive hits.
Direct acting antivirals (DAAs) revolutionized the therapy of chronic hepatitis C infection. However, unexpected high recurrence rates of hepatocellular carcinoma (HCC) after DAA treatment became an issue in patients with advanced cirrhosis and fibrosis. In this study, we aimed to investigate an impact of DAA treatment on the molecular changes related to HCC development and progression in hepatoma cell lines and primary human hepatocytes. We found that treatment with sofosbuvir (SOF), a backbone of DAA therapy, caused an increase in EGFR expression and phosphorylation. As a result, enhanced translocation of EGFR into the nucleus and transactivation of factors associated with cell cycle progression, B-MYB and Cyclin D1, was detected. Serine/threonine kinase profiling identified additional pathways, especially the MAPK pathway, also activated during SOF treatment. Importantly, the blocking of EGFR kinase activity by erlotinib during SOF treatment prevented all downstream events. Altogether, our findings suggest that SOF may have an impact on pathological processes in the liver via the induction of EGFR signaling. Notably, zidovudine, another nucleoside analogue, exerted a similar cell phenotype, suggesting that the observed effects may be induced by additional members of this drug class.
The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence. Moreover, their use is affected by toxic side-effects (brincidofovir, cidofovir), limited availability (tecovirimat), and potentially by resistance formation. Hence, additional, readily available drugs are needed. Here, therapeutic concentrations of nitroxoline, a hydroxyquinoline antibiotic with a favourable safety profile in humans, inhibited the replication of 12 mpox virus isolates from the current outbreak in primary cultures of human keratinocytes and fibroblasts and a skin explant model by interference with host cell signalling. Tecovirimat, but not nitroxoline, treatment resulted in rapid resistance development. Nitroxoline remained effective against the tecovirimat-resistant strain and increased the anti-mpox virus activity of tecovirimat and brincidofovir. Moreover, nitroxoline inhibited bacterial and viral pathogens that are often co-transmitted with mpox. In conclusion, nitroxoline is a repurposing candidate for the treatment of mpox due to both antiviral and antimicrobial activity.
Background & Aims: Elimination of chronic HBV/HDV infection remains a major global health challenge. Targeting excessive hepatitis B surface antigen (HBsAg) release may provide an interesting window of opportunity to break immune tolerance and to achieve a functional cure using additional antivirals.
Methods: We evaluated a HBsAg-specific human monoclonal antibody, as part of either a prophylactic or therapeutic strategy, against HBV/HDV infection in cell culture models and in human-liver chimeric mice. To assess prophylactic efficacy, mice were passively immunized prior to infection with HBV or HBV/HDV (coinfection and superinfection setting). Therapeutic efficacy was assessed in HBV and HBV/HDV-coinfected mice receiving 4 weeks of treatment. Viral parameters (HBV DNA, HDV RNA and HBsAg) were assessed in mouse plasma.
Results: The antibody could effectively prevent HBV/HDV infection in a dose-dependent manner with IC50 values of ∼3.5 ng/ml. Passive immunization showed complete protection of mice from both HBV and HBV/HDV coinfection. Moreover, HDV superinfection was either completely prevented or at least attenuated in HBV-infected mice. Finally, antibody treatment in mice with established HBV/HDV infection resulted in a significant decline in viremia and a concomitant drop in on-treatment HBsAg, with a moderate viral rebound following treatment cessation.
Conclusion: We present data on a valuable antibody candidate that could complement other antivirals in strategies aimed at achieving functional cure of chronic HBV and HDV infection.
Impact and implications: Patients chronically infected with HBV may eventually develop liver cancer and are at great risk of being superinfected with HDV, which worsens and accelerates disease progression. Unfortunately, current treatments can rarely eliminate both viruses from chronically infected patients. In this study, we present data on a novel antibody that is able to prevent chronic HBV/HDV infection in a mouse model with a humanized liver. Moreover, antibody treatment of HBV/HDV-infected mice strongly diminishes viral loads during therapy. This antibody is a valuable candidate for further clinical development.
Although vaccines are currently used to control the coronavirus disease 2019 (COVID-19) pandemic, treatment options are urgently needed for those who cannot be vaccinated and for future outbreaks involving new severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) strains or coronaviruses not covered by current vaccines. Thus far, few existing antivirals are known to be effective against SARS-CoV-2 and clinically successful against COVID-19. As part of an immediate response to the COVID-19 pandemic, a high-throughput, high content imaging–based SARS-CoV-2 infection assay was developed in VeroE6 African green monkey kidney epithelial cells expressing a stable enhanced green fluorescent protein (VeroE6-eGFP cells) and was used to screen a library of 5676 compounds that passed Phase 1 clinical trials. Eight drugs (nelfinavir, RG-12915, itraconazole, chloroquine, hydroxychloroquine, sematilide, remdesivir, and doxorubicin) were identified as inhibitors of in vitro anti–SARS-CoV-2 activity in VeroE6-eGFP and/or Caco-2 cell lines. However, apart from remdesivir, toxicity and pharmacokinetic data did not support further clinical development of these compounds for COVID-19 treatment.